Zelira Therapeutics Eyes FDA Approval for HOPE® 1

Zelira Therapeutics (AU:ZLD) has released an update.

Zelira Therapeutics, a global biopharmaceutical company, is advancing through the US FDA New Drug Approval Program with its HOPE® 1 treatment, targeting irritability associated with Phelan McDermid Syndrome and comorbid Autism Spectrum Disorder. Investors are cautioned to perform their own due diligence, as the company’s forward-looking statements regarding its strategy, intentions, and future plans are subject to inherent risks and uncertainties.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.